Inspection
![Audits and Inspections in Pharmaceutical Industries | Similarities and Differences](https://pharmadigests.com/wp-content/uploads/2024/03/Audits-and-Inspections-in-Pharmaceutical-Industries.png)
Audits and Inspections in Pharmaceutical Industries | Similarities and Differences
Audit: ensure quality and compliance with systematic, independent examination and documented process Inspection: determination of conformity to specified requirements “Audit” can be seen as an umbrella term, whereas “inspection” is one concrete type of audit. Similarities 1) Both involve a review of processes, procedures, and records.2) Both aim to determine ... Read More
![Common Terms Used in USFDA Inspections](https://pharmadigests.com/wp-content/uploads/2024/02/Common-Terms-Used-in-USFDA-Inspections.png)
Common Terms Used in USFDA Inspections
Types of USFDA Inspections The agency also conducts inspections to verify the reliability, integrity and compliance of r&d facilities, testing labs, cmo, clinical and non-clinical research being reviewed in support of pending applications. FDA Forms 482, 483 and 484 Establishment Inspection Report (EIR) A comprehensive report that provides a detailed ... Read More
![Criteria of Maintaining Audit and Inspection Readiness in Pharmaceutical Industry](https://pharmadigests.com/wp-content/uploads/2023/09/IMG_20230904_085409.png)
Criteria of Maintaining Audit and Inspection Readiness in Pharmaceutical Industry
To maintain audit and inspection readiness at all times in pharmaceutical industry, following criteria are to be maintained: 1. Clear Communication Channel 2. Document Control and Management 3. Effective Training and Competency Programs 4. Robust Change Control Processes 5. Real-time Monitoring and Data Analytics 6. A Culture of Continuous Improvement ... Read More
![FDA Findings and Remdies on cGMP Violations](https://pharmadigests.com/wp-content/uploads/2023/07/IMG_20230803_111403.png)
FDA Findings and Remdies on cGMP Violations
The U.S. Food and Drug Administration (FDA) recently inspected a US drug manufacturing facility and identified several significant cGMP violations, resulting in a Warning Letter (#649198). The violations include: Here are five remediation actions that the company should take: Cleaning and Maintenance Procedures: Investigations and Deviations: Production and Process Control ... Read More